



## Anika Therapeutics to Webcast Presentation at Canaccord Adams Musculoskeletal Conference

BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 19, 2009-- Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that Charles Sherwood, president and chief executive officer, will be presenting at the Canaccord Adams Musculoskeletal Conference on Tuesday, February 24, 2009 at 10:20 a.m. PT ( 1:20 p.m. ET ). A live audio webcast of the presentation may be accessed via the Internet at: <http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240>. In addition, the presentation will be available live at the "Investors" section of Anika's website at [www.anikatherapeutics.com](http://www.anikatherapeutics.com).

Within the presentation Dr. Sherwood will discuss the current state of the business, including the Company's **joint health** product franchise and related U.S. clinical trial for **MONOVISC™**, a single-injection treatment for osteoarthritis.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., **Anika Therapeutics, Inc.** develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on **hyaluronic acid (HA)**, a naturally occurring, biocompatible polymer found throughout the body. Anika's products include **ORTHOVISC®**, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; **HYVISC®**, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the **ELEVESS™** family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; **AMVISC®**, **AMVISC® Plus**, **STAARVISC™-II** and **Shellgel™** injectable viscoelastic HA products for ophthalmic surgery; **INCERT®**, an HA-based anti-adhesive for surgical applications; **ORTHOVISC® mini** a treatment for osteoarthritis targeting small joints and available in Europe; **MONOVISC™** a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

Source: Anika Therapeutics, Inc.

Anika Therapeutics, Inc.

Charles H. Sherwood, Ph.D., 781-457-9000

CEO

or

Kevin W. Quinlan, 781-457-9000

CFO